← stocks-llm Find companies like QGEN →

Qiagen (QGEN)

Health Care · Molecular diagnostics and life sciences sample preparation

QIAGEN supplies essential molecular diagnostic and sample preparation tools that enable laboratories and clinicians to detect, analyze, and validate genetic material and biomarkers.

What Qiagen does

QIAGEN is a life sciences company that develops and manufactures sample preparation, molecular diagnostics, and analytical technologies for research, clinical diagnostics, and forensic applications. The company provides instrumentation, assay kits, reagents, and software solutions that enable customers to extract, purify, and analyze nucleic acids and proteins from biological samples.

Themes: ["molecular diagnostics","sample preparation / nucleic acid extraction","PCR and qPCR technology","NGS / genomics","clinical diagnostics","life sciences research tools","infectious disease testing"]

Fundamentals

Dividend: yield +0.6%; pays a dividend.

Ask why QGEN looks like this →

Key risks (from latest filing)

["Cyclical demand for diagnostic assays tied to infection rates and disease prevalence; post-pandemic normalization has pressured revenue growth (4.79% YoY)","Competition from larger life sciences conglomerates and specialized diagnostic companies with greater R&D spending and scale","Dependence on proprietary reagent consumables and assay kits for recurring revenue; customer switching costs moderate but not insurmountable"]

See QGEN's biggest risks from its latest 10-Q →

Competitors & peers

Not quite? Describe exactly what you want →

Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.

Last updated 2026-07-09.

Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.